These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18506391)

  • 41. The function of dopaminergic neural signal transmission in auditory pulse perception: evidence from dopaminergic treatment in Parkinson's patients.
    Geiser E; Kaelin-Lang A
    Behav Brain Res; 2011 Nov; 225(1):270-5. PubMed ID: 21787806
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dopamine improves exploration after expectancy violations and induces psychotic-like experiences in patients with Parkinson's disease.
    Polner B; Moustafa AA; Nagy H; Takáts A; Győrfi O; Kéri S
    Neurosci Lett; 2016 Mar; 616():132-7. PubMed ID: 26820375
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safinamide for the treatment of Parkinson's disease.
    Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dopaminergic medication alters auditory distractor processing in Parkinson's disease.
    Georgiev D; Jahanshahi M; Dreo J; Čuš A; Pirtošek Z; Repovš G
    Acta Psychol (Amst); 2015 Mar; 156():45-56. PubMed ID: 25697781
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of dopaminergic medication on conflict adaptation in Parkinson's disease.
    Ruitenberg MFL; Abrahamse EL; Santens P; Notebaert W
    J Neuropsychol; 2019 Mar; 13(1):121-135. PubMed ID: 28714199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease.
    Weinberger M; Mahant N; Hutchison WD; Lozano AM; Moro E; Hodaie M; Lang AE; Dostrovsky JO
    J Neurophysiol; 2006 Dec; 96(6):3248-56. PubMed ID: 17005611
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dopaminergic modulation of motor network dynamics in Parkinson's disease.
    Michely J; Volz LJ; Barbe MT; Hoffstaedter F; Viswanathan S; Timmermann L; Eickhoff SB; Fink GR; Grefkes C
    Brain; 2015 Mar; 138(Pt 3):664-78. PubMed ID: 25567321
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Iowa Gambling Task in Parkinson's disease: A meta-analysis on effects of disease and medication.
    Evens R; Hoefler M; Biber K; Lueken U
    Neuropsychologia; 2016 Oct; 91():163-172. PubMed ID: 27475264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dopaminergic medication boosts action-effect binding in Parkinson's disease.
    Moore JW; Schneider SA; Schwingenschuh P; Moretto G; Bhatia KP; Haggard P
    Neuropsychologia; 2010 Mar; 48(4):1125-32. PubMed ID: 20018200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Motivational modulation of bradykinesia in Parkinson's disease off and on dopaminergic medication.
    Kojovic M; Mir P; Trender-Gerhard I; Schneider SA; Pareés I; Edwards MJ; Bhatia KP; Jahanshahi M
    J Neurol; 2014 Jun; 261(6):1080-9. PubMed ID: 24687892
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intact action segmentation in Parkinson's disease: Hypothesis testing using a novel computational approach.
    Schiffer AM; Nevado-Holgado AJ; Johnen A; Schönberger AR; Fink GR; Schubotz RI
    Neuropsychologia; 2015 Nov; 78():29-40. PubMed ID: 26432343
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pre- and unplanned walking turns in Parkinson's disease - Effects of dopaminergic medication.
    Conradsson D; Paquette C; Lökk J; Franzén E
    Neuroscience; 2017 Jan; 341():18-26. PubMed ID: 27867059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The alpha2 agonist, clonidine, improves spatial working performance in Parkinson's disease.
    Riekkinen M; Jäkälä P; Kejonen K; Riekkinen P
    Neuroscience; 1999; 92(3):983-9. PubMed ID: 10426538
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.
    Greenamyre JT
    J Neural Transm Gen Sect; 1993; 91(2-3):255-69. PubMed ID: 8099800
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Verbal fluency in Parkinson's disease patients on/off dopamine medication.
    Herrera E; Cuetos F; Ribacoba R
    Neuropsychologia; 2012 Dec; 50(14):3636-40. PubMed ID: 22995942
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Motor program memory storage in Parkinson's disease patients tested with a delayed response task.
    Labutta RJ; Miles RB; Sanes JN; Hallett M
    Mov Disord; 1994 Mar; 9(2):218-22. PubMed ID: 8196687
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Working memory in Parkinson's disease patients: clinical features and response to levodopa.
    Beato R; Levy R; Pillon B; Vidal C; du Montcel ST; Deweer B; Bonnet AM; Houeto JL; Dubois B; Cardoso F
    Arq Neuropsiquiatr; 2008 Jun; 66(2A):147-51. PubMed ID: 18545772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dopamine modulation affects the performance of parkinsonian patients in a precision motor task measured by an antropomorphic device.
    Nombela C; Pedreño-Molina JL; Ros-Bernal F; Molina-Vilaplana J; Fdez-Villalba E; López-Coronado J; Herrero MT
    Hum Mov Sci; 2012 Jun; 31(3):730-42. PubMed ID: 22414696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.
    Lewis SJ; Slabosz A; Robbins TW; Barker RA; Owen AM
    Neuropsychologia; 2005; 43(6):823-32. PubMed ID: 15716155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.